- Trials with a EudraCT protocol (779)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
779 result(s) found for: Cancer Immunotherapy.
Displaying page 1 of 39.
EudraCT Number: 2021-005115-32 | Sponsor Protocol Number: 213824 | Start Date*: 2022-09-16 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A Phase 2, Randomized, Open-label Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated Locally Advanced/Metastatic Prog... | |||||||||||||
Medical condition: Non-small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Ongoing) ES (Ongoing) NL (Ongoing) BE (Ongoing) DE (Ongoing) IT (Ongoing) PL (Ongoing) PT (Ongoing) HU (Ongoing) GR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003809-26 | Sponsor Protocol Number: SP010 | Start Date*: 2013-12-04 | |||||||||||
Sponsor Name:SOTIO a.s. | |||||||||||||
Full Title: Open-label, one-arm, multi-centre phase II clinical trial with second cycle of active cellular immunotherapy DCVAC/PCa in patients with localized prostate cancer after primary radical prostatectomy... | |||||||||||||
Medical condition: Localized prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000254-21 | Sponsor Protocol Number: MO39839 | Start Date*: 2021-04-20 | ||||||||||||||||
Sponsor Name:University Hospital Essen | ||||||||||||||||||
Full Title: Window of opportunity study of preoperative immunotherapy with atezolizumab (Tecentriq®) with or without tocilizumab (Actemra®) in local head and neck squamous cell carcinoma | ||||||||||||||||||
Medical condition: local squamous cell carcinoma of the head and neck | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003408-33 | Sponsor Protocol Number: ESR-21-21536 | Start Date*: 2023-04-25 | |||||||||||
Sponsor Name:TheraOp gGmbH | |||||||||||||
Full Title: PACCELIO - FDG-PET based small volume accelerated immuno chemoradio-therapy in locally advanced NSCLC | |||||||||||||
Medical condition: Locally advanced, unresectable non-small-cell lung cancer (NSCLC) (Stage III) with a PD-L1-expression of ≥ 1% | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005427-36 | Sponsor Protocol Number: NL75654.078.20 | Start Date*: 2021-05-26 |
Sponsor Name:Erasmus MC Cancer Center [...] | ||
Full Title: A multicenter, open label non-randomized phase I/II dose escalation study with extension cohort to determine the safety, tolerability and immune modulating effects of the therapeutic LRPAP1 synthet... | ||
Medical condition: non small cell lung cancer (NSCLC) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003616-13 | Sponsor Protocol Number: TPX-0005-01 | Start Date*: 2020-05-12 | |||||||||||
Sponsor Name:Turning Point Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ... | |||||||||||||
Medical condition: advanced solid tumors | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) NL (Ongoing) DE (Ongoing) PL (Ongoing) ES (Ongoing) BE (Ongoing) HU (Ongoing) DK (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000872-13 | Sponsor Protocol Number: 202000865 | Start Date*: 2021-03-02 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Vaccination against cOvid In CancEr | ||
Medical condition: solid tumors | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004566-99 | Sponsor Protocol Number: CO39612 | Start Date*: 2020-03-27 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC COLORECTAL CA... | |||||||||||||
Medical condition: Colorectal cancer (CRC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023124-24 | Sponsor Protocol Number: LUMCCHIP | Start Date*: 2011-03-02 | |||||||||||
Sponsor Name:Academisch Ziekenhuis Leiden acting under the name of Leids Universitair Medisch Centrum | |||||||||||||
Full Title: Chemo-Immunotherapy, gemcitabine with pegylated interferon alpha-2b (Peg-Intron) with and without p53 synthetic long peptide (p53 SLP) vaccine, for patients with platinum resistant ovarian cancer. ... | |||||||||||||
Medical condition: Recurrent platinum resistant, p53 positive ovarian cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003159-44 | Sponsor Protocol Number: SOGUG-2017-A-IEC(VEJ)-1 | Start Date*: 2018-09-27 | |||||||||||
Sponsor Name:Spanish Oncology Genitourinary Group | |||||||||||||
Full Title: Phase II trial of durvalumab (Medi4736) plus tremelimumab with concurrent radiotherapy in patients with localized muscle invasive bladder cancer treated with a selective bladder preservation approach | |||||||||||||
Medical condition: Localized muscle invasive bladder cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001034-35 | Sponsor Protocol Number: RG_19-138 | Start Date*: 2020-10-15 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: Accelerating the Development and implementation of Personalised Treatments of DNA Damage Response agents and radiotherapy +/- immunotherapy for head and neck squamous cell cancer | |||||||||||||
Medical condition: Head and neck squamous cell carcinoma (HNSCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003440-92 | Sponsor Protocol Number: INFINITY | Start Date*: 2020-12-22 | ||||||||||||||||
Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST | ||||||||||||||||||
Full Title: TremelImumab aNd durvalumab combination For the non-operatIve management (NOM) of Microsatellite InstabiliTY (MSI)-high resectable gastric or gastroesophageal junction cancer: The multicentre, sing... | ||||||||||||||||||
Medical condition: The disease under clinical investigation is represented by resectable gastric or gastroesophageal junction (Siewert II-III) adenocarcinoma staged as cT = 2, any cN, or any cT, cN1-3 (TNM classifica... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000295-38 | Sponsor Protocol Number: IMPEDE | Start Date*: 2020-05-27 | |||||||||||
Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA | |||||||||||||
Full Title: Phase II trial, open label, single-arm, of Immune Checkpoint Inhibitor In High Risk Oral Premalignant Lesions | |||||||||||||
Medical condition: Clinical and histological evidence of Oral Premalignant Lesions (OPL) with high risk of malignant transformation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004967-65 | Sponsor Protocol Number: SP004 | Start Date*: 2012-01-11 | |||||||||||
Sponsor Name:SOTIO a.s. | |||||||||||||
Full Title: Randomized, open-label, parallel-group, multi-centre phase II clinical trial with active cellular immunotherapy DCVAC/PCa in patients with localized high-risk prostate cancer after primary radiothe... | |||||||||||||
Medical condition: localized high-risk prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002478-29 | Sponsor Protocol Number: CA224-063 | Start Date*: 2019-11-27 | |||||||||||
Sponsor Name:University Hospital Essen | |||||||||||||
Full Title: Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological response (NEOpredict-Lung) | |||||||||||||
Medical condition: non-small cell lung cancer (NSCLC) of clinical stages IB, II and selected stage III A | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) BE (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002474-39 | Sponsor Protocol Number: VBN-01 | Start Date*: 2018-01-17 | |||||||||||||||||||||||||||||||
Sponsor Name:Nykode Therapeutics AS | |||||||||||||||||||||||||||||||||
Full Title: An open-label first-in-human phase 1/2a study to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO or VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy... | |||||||||||||||||||||||||||||||||
Medical condition: Locally advanced or metastatic solid tumours including melanoma, NSCLC, clear renal cell carcinoma, urothelial cancer or SCCHN | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004377-13 | Sponsor Protocol Number: CA209-9HX | Start Date*: 2018-11-21 | |||||||||||
Sponsor Name:SOGUG (Spanish Genitourinary Oncologic Group) | |||||||||||||
Full Title: A multi-arm, multi-stage, randomized phase II/III trial of immunotherapy strategies in metastatic hormone-sensitive prostate cancer. | |||||||||||||
Medical condition: metastatic hormone-sensitive prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002328-33 | Sponsor Protocol Number: VB_C-02 | Start Date*: 2020-02-07 | |||||||||||
Sponsor Name:Nykode Therapeutics ASA | |||||||||||||
Full Title: A Multi-Centre, Open-label Phase 2a Trial of the Combination of VB10.16 and Atezolizumab in Patients with Advanced or Recurrent, Non-resectable HPV16-Positive Cervical Cancer | |||||||||||||
Medical condition: Advanced or recurrent non-resectable HPV16-positive cervical cancer, who failed or are not eligible for current standard of care | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) NO (Completed) BG (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001774-41 | Sponsor Protocol Number: MM04 | Start Date*: 2018-04-23 | |||||||||||
Sponsor Name:Amphera B.V. | |||||||||||||
Full Title: A Randomized, Open-Label Phase II/III Study With Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects With Mesothelioma as Maintenance Treatment (MesoPher) After Chemoth... | |||||||||||||
Medical condition: Pleural malignant mesothelioma. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) BE (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003310-14 | Sponsor Protocol Number: SHO20190708 | Start Date*: 2019-12-05 |
Sponsor Name:Department of Dermatology, Bispebjerg Hospital | ||
Full Title: Laser immunotherapy with and without topical anti-PD1 in basal cell carcinomas | ||
Medical condition: Basal cell carcinoma in 24-30 patients | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.